ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:11 PM ET on Jun 18, 2013
Delayed at least 20 minutes.
Provided by eSignal.
Jun 5, 2013
ChemoCentryx to Present at Two Upcoming Healthcare Conferences and Ring Opening Bell at the NASDAQ Stock Market
May 28, 2013
ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein, MD, to Company's Board of Directors
May 21, 2013
ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
View all »Events & Presentations
Jun 19, 2013 at 8:20 AM ET
Wells Fargo Securities 2013 Healthcare Conference
^ Return to Top